Aegerion Pharmaceuticals, a subsidiary of Novelion Therapeutics, is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. Headquartered in Cambridge, Massachusetts, Aegerion employs about 200 people in a number of countries throughout the world. For more information about the company, please visit www.novelion.com.